Delta Sleep-Inducing Peptide — Dosing & Research | Peptide Chats
Research information only. Not medical advice. 18+ only. Not FDA-approved for human therapeutic use.

Delta Sleep-Inducing Peptide (DSIP)

Also known as: DSIP, delta sleep-inducing peptide, delta-sleep-inducing peptide, WAGGDASGE, Deltaran

Neuropeptide / Regulatory peptide (nonapeptide)

Research chemicalLast updated: October 19, 2026Based on 41 peer-reviewed studies

What it is

DSIP is a neuropeptide people use for sleep improvement, pain reduction, and stress recovery. It was originally identified as a sleep-promoting signal, though its relationship to sleep is not firmly established. Not FDA-approved; evidence from small and older human studies; commonly available as a research compound.

The scientific side

DSIP (Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu) is a nonapeptide with multifunctional regulatory activity. It was originally isolated from rabbit cerebral venous blood in 1977 and initially characterized as a sleep-promoting factor, though its link to sleep has not been definitively established. Its biosynthetic origin remains obscure; no DSIP gene or protein precursor has been confirmed, though JmjC-domain-containing histone demethylases (JMJD1B gene) have been proposed as possible precursors based on sequence homology (PMID 21262293; PMID 24397026). DSIP has been shown to influence oxidative phosphorylation in rat brain mitochondria, significantly increasing the rate of phosphorylated respiration (V3) and the respiratory control ratio. It modulates neurotransmitter systems including Met-enkephalin release, spinal noradrenergic pathways mediating antinociception, and GABAergic Cl⁻ flux. DSIP also affects thermoregulation via 5-HT1A and dopaminergic mechanisms (PMID 8015981; PMID 2322843). Stress-protective and adaptive activity has been described across multiple stressor types. DSIP displays a saturable, high-affinity transport mechanism at the blood-brain barrier, and also enters CSF to a slight or moderate extent in intact form. It is rapidly degraded in blood, primarily by cleavage of the N-terminal tryptophan via aminopeptidases (PMID 3628078; PMID 8474631). Plasma DSIP-like immunoreactivity decreases at the initiation of sleep. A phosphorylated analogue (P-DSIP, phosphorylated at Ser7) shows slower degradation and different pharmacodynamic properties (PMID 3628078; PMID 2496423). Recovery-enhancing and circadian/mitochondrial regulatory roles are noted in orthopaedic-relevant reviews.

Class: Neuropeptide / Regulatory peptide (nonapeptide)

Administration & storage

Administration
Slow intravenous infusion (PMID: 6895513)Intravenous injection (PMID: 7028502; PMID: 3792404; PMID: 6548969; PMID: 6548967)Subcutaneous injection — animal studies (PMID: 6548967)Intraperitoneal injection — animal studies (PMID: 22432135; PMID: 12668217; PMID: 15911358)Intranasal administration — animal studies (PMID: 34500605)Intracerebroventricular injection/infusion — animal studies (PMID: 2496423; PMID: 11525128; PMID: 2713670)
Storage
Storage conditions for DSIP are not described in the reviewed abstracts. No storage or stability guidance appears in the provided literature.
Cautions
In human clinical studies, DSIP was generally reported as well-tolerated; headaches were reported by a few patients in the withdrawal treatment study; no psychologic, physiologic, or biochemical side effects were observed in early volunteer studies.,DSIP is rapidly degraded in blood by aminopeptidase cleavage of the N-terminal tryptophan, contributing to variable in vivo effects; this instability may result in inconsistent pharmacological outcomes (PMID: 3628078; PMID: 8474631).,Slow intravenous injection was described as essential in human studies; rapid injection may alter tolerability or efficacy.,A bell-shaped dose-response curve has been reported in multiple animal experiments, meaning doses above or below the effective range may be inactive or produce different effects (PMID: 6145137; PMID: 2322843; PMID: 6548967).,No formal human pharmacokinetic, long-term safety, or randomized controlled trial data were identified in the reviewed abstracts; use outside of controlled research settings is not supported by the available evidence. Sterile technique is essential for any injectable preparation.

Legal & regulatory status

US FDA

Not stated in reviewed literature — requires manual verification

WADA

Not stated in reviewed literature — requires manual verification

Health Canada

Not stated in reviewed literature — requires manual verification